Overexpression of Aiolos in Nalm-6 acute lymphoblastic leukaemia cells reduces apoptosis by suppressing phosphatase and tensin homologue deleted on chromosome 10 and activating the phosphatidylinositol-3-kinase/Akt signalling pathway

Wang,Ran; Guo,Gang; Li,Hao; Li,Xiangxin; Yu,Yuan; Li,Dong

doi:10.3892/mmr.2015.3214

Overexpression of Aiolos in Nalm-6 acute lymphoblastic leukaemia cells reduces apoptosis by suppressing phosphatase and tensin homologue deleted on chromosome 10 and activating the phosphatidylinositol-3-kinase/Akt signalling pathway

Authors:
- Ran Wang
- Gang Guo
- Hao Li
- Xiangxin Li
- Yuan Yu
- Dong Li
View Affiliations

Affiliations: Department of Hematology, Qilu Hospital, Shandong University, Ji'nan, Shandong 250012, P.R. China, Cryomedicine Laboratory, Qilu Hospital, Shandong University, Ji'nan, Shandong 250012, P.R. China
Published online on: January 16, 2015 https://doi.org/10.3892/mmr.2015.3214
Pages: 3457-3464

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to elucidate the molecular mechanism of Aiolos in the regulation of B‑cell leukaemia. A lentiviral system was used for overexpression of the Aiolos gene in Nalm‑6 cells to determine the effects of Aiolos on proliferation, apoptosis and the cell cycle. The expression and activation of phosphatase and tensin homolog deleted on chromosome ten (PTEN) and Akt were also investigated. Upregulation of Aiolos inhibited cell growth and arrested an increased number of Nalm‑6 cells at the G0/G1 phase. The apoptotic cell quantities were also significantly lower in the Aiolos‑transfected Nalm‑6 cells. In addition, Aiolos overexpression downregulated PTEN, but increased the expression and phosphorylation of Akt in the Nalm‑6 cells. The Akt inhibitor, Akti‑1/2, reduced the percentage of viable Aiolos‑overexpressed Nalm‑6 cells, however, it had no effect on cell cycle arrest or proliferation. Aiolos upregulation in the Nalm‑6 cells inhibited cell proliferation, suppressed apoptosis and arrested the cell cycle at the G0/G1 phase. Aiolos improved the survival of Nalm‑6 cells via PTEN‑ and Akt‑dependent processes.

View Figures

View References

1	Kaatsch P: Epidemiology of childhood cancer. Cancer Treat Rev. 36:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
2	Pui CH, Robison LL and Look AT: Acute lymphoblastic leukaemia. Lancet. 371:1030–1043. 2008. View Article : Google Scholar : PubMed/NCBI
3	Cobaleda C and Sánchez-Garcia I: B-cell acute lymphoblastic. leukaemia: towards understanding its cellular origin. Bioessays. 31:600–609. 2009. View Article : Google Scholar : PubMed/NCBI
4	Georgopoulos K, Moore DD and Derfler B: Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science. 258:808–812. 1992. View Article : Google Scholar : PubMed/NCBI
5	Kelley CM, Ikeda T, Koipally J, et al: Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitors. Curr Biol. 8:508–515. 1998. View Article : Google Scholar : PubMed/NCBI
6	Morgan B, Sun L, Avitahl N, et al: Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J. 16:2004–2013. 1997. View Article : Google Scholar : PubMed/NCBI
7	Georgopoulos K, Winandy S and Avitahl N: The role of the Ikaros gene in lymphocyte development and homeostasis. Annu Rev Immunol. 15:155–176. 1997. View Article : Google Scholar : PubMed/NCBI
8	Wang JH, Avitahl NA, Cariappa C, et al: Aiolos regulates B cell activation and maturation to effector state. Immunity. 9:543–553. 1998. View Article : Google Scholar : PubMed/NCBI
9	Nakase K, Ishimaru F, Avitahl N, et al: Dominant negative isoform of the Ikaros gene in patients with adult B-cell acute lymphoblastic leukemia. Cancer Res. 60:4062–4065. 2000.PubMed/NCBI
10	Nuckel H, Frey UH, Sellmann L, et al: The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia. Br J Haematol. 144:268–270. 2009. View Article : Google Scholar
11	Billot K, Soeur J, Chereau F, et al: Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. Blood. 117:1917–1927. 2011. View Article : Google Scholar
12	Antica M, Cicin-Sain L, Kapitanovic S, et al: Aberrant Ikaros, Aiolos and Helios expression in Hodgkin and non-Hodgkin lymphoma. Blood. 111:3296–3297. 2008. View Article : Google Scholar : PubMed/NCBI
13	Caballero R, Setien F, Lopez-Serra L, et al: Combinatorial effects of splice variants modulate function of Aiolos. J Cell Sci. 120:2619–2630. 2007. View Article : Google Scholar : PubMed/NCBI
14	Duhamel M, Arrouss I, Merle-Béral H, et al: The Aiolos transcription factor is up-regulated in chronic lymphocytic leukemia. Blood. 111:3225–3228. 2008. View Article : Google Scholar : PubMed/NCBI
15	Cobb BS and Smale ST: Ikaros-family proteins: in search of molecular functions during lymphocyte development. Curr Top Microbiol Immunol. 290:29–47. 2005.
16	Thompson EC, Cobb BS, Sabbattini P, et al: Ikaros DNA-binding proteins as integral components of B-cell developmental-stage-specific regulatory circuits. Immunity. 26:335–344. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ma S, Pathak S, Mandal M, et al: Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol. 30:4149–4158. 2010. View Article : Google Scholar : PubMed/NCBI
18	Myung DS, Park YL, Chung CY, et al: Expression of livin in colorectal cancer and its relationship to tumor cell behavior and prognosis. PLoS One. 8:e732622013. View Article : Google Scholar : PubMed/NCBI
19	Toyoshima H and Hunter T: P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:67–74. 1994. View Article : Google Scholar : PubMed/NCBI
20	Herzog S, Reth M and Jumaa H: Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signaling. Nat Rev Immunol. 9:195–205. 2009. View Article : Google Scholar : PubMed/NCBI
21	Cooper AB, Sawai CM, Sicinska E, et al: A unique function for cyclin D3 in early B cell development. Nat Immunol. 7:489–497. 2006. View Article : Google Scholar : PubMed/NCBI
22	Habib T, Park H, Tsang M, et al: Myc stimulates B lymphocyte differentiation and amplifies calcium signaling. J Cell Biol. 179:717–731. 2007. View Article : Google Scholar : PubMed/NCBI
23	Narvi E, Nera KP, Terho P, et al: Aiolos controls gene conversion and cell death in DT40 B cells. Scand J Immunol. 65:503–513. 2007. View Article : Google Scholar : PubMed/NCBI
24	Kikuchi H, Yamashita K, Nakayama M, et al: Lacking of Aiolos accelerates pre-mature B cell apoptosis mediated by BCR signaling through elevation in cytochrome c release. Biochim Biophys Acta. 1793:1304–1314. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang P, Pavletic ZS and Joshi SS: Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation. Leuk Lymphoma. 43:1827–1835. 2002. View Article : Google Scholar
26	Ausserlechner MJ, Obexer P, Böck G, et al: Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells. Cell Death Differ. 11:165–174. 2004. View Article : Google Scholar
27	Shehata M, Schnabl S, Demirtas D, et al: Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood. 116:2513–2521. 2010. View Article : Google Scholar : PubMed/NCBI
28	Zhiyong C, Wentong L, Xiaoyang Y, et al: PTEN Regulates VEGF, VEGFR1 Expression and Its Clinical Significance in Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts). 114:Abstract 1001. 2009.
29	Gutierrez A, Sanda T, Grebliunaite R, et al: High frequency of PTEN, PI3 K and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 114:647–650. 2009. View Article : Google Scholar : PubMed/NCBI
30	Karoui M, Tresallet C, Julie C, et al: Loss of heterozygosity on 10q and mutational status of PTEN and BM PR1A in colorectal primary tumours and metastases. Br J Cancer. 90:1230–1234. 2004. View Article : Google Scholar : PubMed/NCBI
31	Poetsch M, Lorenz G and Kleist B: Detection of new PTEN/MM AC 1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. Cancer Genet Cytogenet. 132:20–24. 2002. View Article : Google Scholar : PubMed/NCBI
32	Hou R, Zhang J, Yin T, et al: Upregulation of PTEN by peroxynitrite contributes to cytokine-induced apoptosis in pancreatic beta-cells. Apoptosis. 15:877–886. 2010. View Article : Google Scholar : PubMed/NCBI
33	Koul D, Yao Y, Abbruzzese JL, et al: Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappa B activation without interfering with the IkappaB degradation pathway. J Biol Chem. 276:11402–11408. 2001. View Article : Google Scholar : PubMed/NCBI
34	Lee SY, Kang EJ, Hur GY, et al: Peroxisome proliferator-activated receptor-gamma inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol. 291:L84–L90. 2006. View Article : Google Scholar : PubMed/NCBI
35	Kim S, Domon-Dell C, Kang J, et al: Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop. J Biol Chem. 279:4285–4291. 2004. View Article : Google Scholar
36	Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
37	Stambolic V, Suzuki A, de la Pompa JL, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:29–39. 1998. View Article : Google Scholar : PubMed/NCBI
38	Sun H, Lesche R, Li DM, et al: PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA. 96:6199–6204. 1999. View Article : Google Scholar : PubMed/NCBI
39	Gold MR, Scheid MP, Santos L, et al: The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase. J Immunol. 163:1894–1905. 1999.PubMed/NCBI
40	Leslie NR and Downes CP: PTEN function: how normal cells control it and tumour cells lose it. Biochem J. 382:1–11. 2004. View Article : Google Scholar : PubMed/NCBI
41	Datta SR, Dudek H, Tao X, et al: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
42	Salmena L, Carracedo A and Pandolfi PP: Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008. View Article : Google Scholar : PubMed/NCBI
43	Perry JM, He XC, Sugimura R, et al: Cooperation between both Wnt/{beta}-catenin and PTEN/PI3 K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev. 25:1928–1942. 2011. View Article : Google Scholar : PubMed/NCBI
44	Tothova Z and Gilliland DG: FoxO transcription factors and stem cell homeostasis: Insights from the hematopoietic system. Cell Stem Cell. 16:140–152. 2007. View Article : Google Scholar